Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
Type:
Grant
Filed:
December 17, 2019
Date of Patent:
August 17, 2021
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Bruno Paillard, Laurence Del Frari, Valérie Brunner, Adrian Newman Tancredi, Mark Varney
Abstract: The present invention concerns a compound of following formula (I): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ?a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ?—(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ?an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ?a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
Type:
Application
Filed:
October 27, 2020
Publication date:
April 15, 2021
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Michel PEREZ, Ian Rilatt, Marie Lamothe
Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
Type:
Application
Filed:
October 28, 2020
Publication date:
February 11, 2021
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Ian RILATT, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Marie Lamothe
Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an anti-body-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said anti-body-drug-conjugate for the treatment of cancer.
Type:
Grant
Filed:
January 31, 2018
Date of Patent:
February 9, 2021
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Ian Rilatt, Michel Perez, Marie Lamothe
Abstract: The invention relates to a compound selected from among celastrol, the derivatives thereof and the pharmaceutically acceptable salts of celastrol and its derivatives, or a composition comprising such a compound for use in the topical prevention and/or treatment of a tumour or precancerous disease of the skin.
Abstract: The present invention relates to a method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a selective D3 antagonist, wherein said subject has at least one negative symptom (NS) among the following core negative symptoms in PANSS: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive withdrawal (N4), and Lack of Spontaneity (N6); with moderate or higher severity. Methods for improving the probability of success and/or the effect of a treatment of schizophrenia in a subject in need thereof are also described.
Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
Type:
Grant
Filed:
October 26, 2016
Date of Patent:
December 8, 2020
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Alexandra Jouhanneaud, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert, Jean-François Haeuw, Ian Rilatt, Michel Perez, Marie Lamothe
Abstract: The present invention relates to a method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a selective D3 antagonist, wherein said subject has at least one negative symptom (NS) among the following core negative symptoms in PANSS: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive withdrawal (N4), and Lack of Spontaneity (N6); with moderate or higher severity. Methods for improving the probability of success and/or the effect of a treatment of schizophrenia in a subject in need thereof are also described.
Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.
Type:
Application
Filed:
April 1, 2020
Publication date:
October 1, 2020
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Peter LOWE, Jean-François HAEUW, Alicia CONTET, Céline BERTAUX, Barbara AKLA, Marie-Claire JANIN-BUSSAT
Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
Type:
Grant
Filed:
December 11, 2015
Date of Patent:
September 8, 2020
Assignee:
Pierre Fabre Medicament
Inventors:
John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
Type:
Application
Filed:
February 26, 2020
Publication date:
August 27, 2020
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT, Marie LAMOTHE
Abstract: The present disclosure relates to IGF-IR (insulin like growth factor receptor-1) antibodies characterized by CDR sequences a, to be used in detection methods of IGF-IR expressing tumoral cells.
Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
Type:
Application
Filed:
December 17, 2019
Publication date:
May 7, 2020
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Bruno PAILLARD, Laurence DEL FRARI, Valérie BRUNNER, Adrian NEWMAN TANCREDI, Mark VARNEY
Abstract: The invention relates to a compound selected from among celastrol, the derivatives thereof and the pharmaceutically acceptable salts of celastrol and its derivatives, or a composition comprising such a compound for use in the topical prevention and/or treatment of a tumour or precancerous disease of the skin.
Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
Type:
Grant
Filed:
April 27, 2015
Date of Patent:
April 28, 2020
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Thierry Champion, Alain Robert, Marie Lamothe
Abstract: The invention relates to a use of Copaifera oleoresin for producing a medicament for preventing and/or treating pathologies of the prostate, particularly benign prostatic hyperplasia and/or prostate cancer.
Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
Type:
Application
Filed:
July 23, 2019
Publication date:
February 6, 2020
Applicant:
Pierre Fabre Medicament
Inventors:
John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA
Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
Type:
Grant
Filed:
July 9, 2015
Date of Patent:
February 4, 2020
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Bruno Paillard, Laurence Del Frari, Valérie Brunner, Adrian Newman Tancredi, Mark Varney
Abstract: The invention concerns a compound of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof as well as a pharmaceutical composition containing such a compound, and the use of such a compound as a drug, notably as a DNMT inhibitor, in particular in the treatment of cancer.
Type:
Grant
Filed:
October 3, 2016
Date of Patent:
January 28, 2020
Assignees:
PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventors:
Ludovic Halby, Yoann Menon, El Bachir Kaloun, Christophe Long, Paola B. Arimondo